Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.

Psychedelic therapies have emerged as a promising frontier in mental health treatment, sparking interest from researchers and investors alike. However, Ben Hargreaves finds the FDA rejection of ...